People · Operator
Named in public records as an officer, director or promoter · active 2018–2021 · Biotechnology, Pharma
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Vir Biotechnology, Inc. | — | Biotechnology | Series D+ | $348.4M | $1.3B | 2018 |
| Interline Therapeutics, Inc. | — | Pharma | Series C | $92.6M | $1.1B | 2021 |
Jay Parrish at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Jay Parrish on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Robert Nelsen | 1 | 22 |
| Kristina Burow | 1 | 16 |
| Robert More | 1 | 7 |
| James Tananbaum | 1 | 6 |
| Vicki Sato | 1 | 6 |
| George Scangos | 1 | 4 |
| Saira Ramasastry | 1 | 4 |
| Thomas Daniel | 1 | 4 |
| Robert Perez | 1 | 3 |
| Dipchand Nishar | 1 | 3 |
| Vikram Bajaj | 1 | 3 |
| Michael Kamarck | 1 | 2 |
| Michael Varney | 1 | 2 |
| Philip Sharp | 1 | 2 |
| Howard Horn | 1 | 1 |
| Phillip Pang | 1 | 1 |
| Herbert Virgin | 1 | 1 |
| Phillip Sharp | 1 | 1 |
| Alex Bangs | 1 | 1 |
| Klaus Frueh | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.